Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.

Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E.

Eur Urol. 2015 Apr;67(4):740-9. doi: 10.1016/j.eururo.2014.05.010. Epub 2014 Jun 2. Review.

PMID:
24882670
2.

Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.

PMID:
28410911
3.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.

Ann Oncol. 2014 Mar;25(3):663-8. doi: 10.1093/annonc/mdt578. Epub 2014 Jan 23.

4.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.

5.

Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.

Tirumani SH, Souza D, Krajewski KM, Jagannathan JP, Ramaiya NH, Shinagare AB.

Abdom Radiol (NY). 2016 Feb;41(2):295-302. doi: 10.1007/s00261-015-0569-7.

PMID:
26867911
6.

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY.

Eur Urol. 2014 Jun;65(6):1086-92. doi: 10.1016/j.eururo.2013.07.031. Epub 2013 Jul 30.

PMID:
23916693
7.

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.

Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY.

Cancer. 2013 Aug 15;119(16):2999-3006. doi: 10.1002/cncr.28151. Epub 2013 May 21.

8.

Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.

Jiang HM, Wei JH, Zhang ZL, Fang Y, Zhou BF, Chen ZH, Lu J, Liao B, Zhou FJ, Luo JH, Chen W.

Int Urol Nephrol. 2016 Feb;48(2):191-9. doi: 10.1007/s11255-015-1161-3. Epub 2015 Nov 20. Review.

PMID:
26589610
9.

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI.

Clin Genitourin Cancer. 2015 Apr;13(2):e79-85. doi: 10.1016/j.clgc.2014.08.011. Epub 2014 Sep 23.

PMID:
25450036
10.

Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.

Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ.

Am J Clin Oncol. 2011 Oct;34(5):454-9. doi: 10.1097/COC.0b013e3181f47aa4.

11.

Targeted therapy for advanced renal cell carcinoma.

Coppin C, Le L, Porzsolt F, Wilt T.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006017. doi: 10.1002/14651858.CD006017.pub2. Review.

PMID:
18425931
12.

Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.

Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, Lotan Y, Margulis V.

Urol Oncol. 2014 Jan;32(1):30.e23-8. doi: 10.1016/j.urolonc.2012.11.002. Epub 2013 Feb 18.

PMID:
23428539
13.

Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.

Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS.

BJU Int. 2012 Oct;110(7):956-60. doi: 10.1111/j.1464-410X.2012.10937.x. Epub 2012 Feb 2.

15.

High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.

Kruck S, Merseburger AS, Hennenlotter J, Scharpf M, Eyrich C, Amend B, Sievert KD, Stenzl A, Bedke J.

BJU Int. 2012 May;109(10):1565-70. doi: 10.1111/j.1464-410X.2011.10649.x. Epub 2011 Oct 7.

16.

The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.

Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlb├Ąck B.

Eur J Cancer. 2014 Jul;50(10):1758-65. doi: 10.1016/j.ejca.2014.03.281. Epub 2014 Apr 30.

PMID:
24793999
17.

Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.

de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB.

Am J Surg Pathol. 2001 Mar;25(3):275-84.

PMID:
11224597
18.

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.

Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V.

J Clin Oncol. 2002 May 1;20(9):2376-81.

PMID:
11981011
19.

Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.

Maruschke M, Reuter D, Koczan D, Hakenberg OW, Thiesen HJ.

BJU Int. 2011 Jul;108(2 Pt 2):E29-35. doi: 10.1111/j.1464-410X.2010.09794.x. Epub 2011 Mar 16.

20.

Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.

Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, Kwon ED.

Cancer. 2007 Aug 15;110(4):783-90.

Supplemental Content

Support Center